EntryPoint Capital LLC Purchases New Shares in Mesoblast Limited (NASDAQ:MESO)

EntryPoint Capital LLC acquired a new position in shares of Mesoblast Limited (NASDAQ:MESO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 12,325 shares of the company’s stock, valued at approximately $244,000.

Other institutional investors have also recently made changes to their positions in the company. Lindbrook Capital LLC boosted its holdings in Mesoblast by 70.9% during the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock worth $43,000 after purchasing an additional 901 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock worth $133,000 after buying an additional 1,213 shares in the last quarter. R Squared Ltd purchased a new position in shares of Mesoblast in the 4th quarter worth approximately $30,000. Prosperity Wealth Management Inc. grew its holdings in shares of Mesoblast by 2.0% in the fourth quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company’s stock valued at $1,846,000 after acquiring an additional 1,795 shares in the last quarter. Finally, LPL Financial LLC increased its position in shares of Mesoblast by 7.7% during the fourth quarter. LPL Financial LLC now owns 38,882 shares of the company’s stock valued at $770,000 after acquiring an additional 2,795 shares during the last quarter. Institutional investors own 1.43% of the company’s stock.

Mesoblast Stock Performance

MESO stock opened at $12.11 on Friday. The stock has a fifty day moving average of $16.31 and a 200-day moving average of $13.11. Mesoblast Limited has a fifty-two week low of $4.60 and a fifty-two week high of $22.00. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on MESO shares. Piper Sandler reissued an “overweight” rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Cantor Fitzgerald raised shares of Mesoblast to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Mesoblast Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.